Dr Lalchandani Labs Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Dr Lalchandani Labs heeft een totaal eigen vermogen van ₹96.9M en een totale schuld van ₹36.3M, wat de schuld-eigenvermogensverhouding op 37.5% brengt. De totale activa en totale passiva bedragen respectievelijk ₹153.7M en ₹56.8M.

Belangrijke informatie

37.5%

Verhouding schuld/eigen vermogen

₹36.30m

Schuld

Rente dekkingsratio	n/a
Contant	₹28.21m
Aandelen	₹96.92m
Totaal verplichtingen	₹56.82m
Totaal activa	₹153.73m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹102.2M ) 541299 } overtreffen de korte termijn passiva ( ₹52.6M ).

Langlopende schulden: De kortetermijnactiva 541299 ( ₹102.2M ) overtreffen de langetermijnschulden ( ₹4.2M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 8.3% ) 541299 wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 541299 is de afgelopen 5 jaar gestegen van 22.2% naar 37.5%.

Schuldendekking: De schuld van 541299 wordt goed gedekt door de operationele kasstroom ( 78.9% ).

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van 541299 op haar schulden goed worden gedekt door EBIT.

Dr Lalchandani Labs Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Chairman & MD recently bought ₹317k worth of stock

First half 2025 earnings released: EPS: ₹0.35 (vs ₹0.20 loss in 1H 2024)

Investor sentiment improves as stock rises 20%

Dr Lalchandani Labs Limited to Report Q2, 2025 Results on Oct 14, 2024

Dr Lalchandani Labs Limited to Report First Half, 2025 Results on Oct 14, 2024

Dr Lalchandani Labs Limited, Annual General Meeting, Sep 30, 2024

Full year 2024 earnings released: EPS: ₹1.43 (vs ₹3.61 loss in FY 2023)

New minor risk - Financial data availability

Dr Lalchandani Labs Limited to Report Second Half, 2024 Results on May 30, 2024

Dr Lalchandani Labs Limited Approves Appointment of Namita Anand as Company Secretary and Compliance Officer

Dr Lalchandani Labs Limited Announces the Resignation of Archana R Jha as Company Secretary and Compliance Officer

Less than half of directors are independent

Dr Lalchandani Labs Limited Announces Resignation of Monika Joshi as Company Secretary and Compliance Officer

Dr Lalchandani Labs Limited Announces Resignation of Monika Joshi as Company Secretary and Compliance Officer

First half 2024 earnings released: ₹0.20 loss per share (vs ₹2.24 loss in 1H 2023)

New major risk - Financial position

Less than half of directors are independent

Less than half of directors are independent

Dr Lalchandani Labs Limited Announces Resignation of Archana Jha from the Office of Company Secretary

Dr Lalchandani Labs Limited, Annual General Meeting, Sep 30, 2023

Dr Lalchandani Labs Limited Appoints Monika Joshi as Company Secretary and Compliance Officer, Effective August 27, 2023

Less than half of directors are independent

Less than half of directors are independent

New major risk - Revenue and earnings growth

Full year 2023 earnings released: ₹3.61 loss per share (vs ₹2.15 profit in FY 2022)

Less than half of directors are independent

Dr Lalchandani Labs Limited to Report Fiscal Year 2023 Results on May 30, 2023

Less than half of directors are independent

Less than half of directors are independent

Dr Lalchandani Labs Limited Announces Management Changes

Dr Lalchandani Labs Limited Appoints Archana Jha as Company Secretary & Compliance Officer

First half 2023 earnings released

Less than half of directors are independent

Dr Lalchandani Labs Limited to Report First Half, 2023 Results on Nov 14, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: ₹2.15 (vs ₹2.33 in FY 2021)

Dr Lalchandani Labs Limited, Annual General Meeting, Sep 30, 2022

Less than half of directors are independent

Dr Lalchandani Labs Limited Announces Resignation of CS Swati Poddar as Company Secretary and Compliance Officer

Dr Lalchandani Labs Limited Resumes in Full Capacity At the Lab in Punjabi Bagh

Investor sentiment deteriorated over the past week

Dr Lalchandani Labs Limited to Report Fiscal Year 2022 Results on May 30, 2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS ₹2.33 (vs ₹1.09 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: ₹13.00

Dr Lalchandani Labs Limited to Report First Half, 2021 Results on Nov 13, 2020

Market pulls back on stock over the past week

New 90-day high: ₹12.10

Full year earnings released - EPS ₹1.09

Dr Lalchandani Labs Limited to Report Fiscal Year 2020 Results on Jun 30, 2020

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven